Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 198


Mouse models in squamous cell lung cancer: impact for drug discovery.

Singh AP, Adrianzen Herrera D, Zhang Y, Perez-Soler R, Cheng H.

Expert Opin Drug Discov. 2018 Apr;13(4):347-358. doi: 10.1080/17460441.2018.1437137. Epub 2018 Feb 15.


Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.

Cheng H, Borczuk A, Janakiram M, Ren X, Lin J, Assal A, Halmos B, Perez-Soler R, Zang X.

Clin Cancer Res. 2018 Jan 26. doi: 10.1158/1078-0432.CCR-17-2924. [Epub ahead of print]


TRIB2 contributes to cisplatin resistance in small cell lung cancer.

Liang Y, Yu D, Perez-Soler R, Klostergaard J, Zou Y.

Oncotarget. 2017 Nov 27;8(65):109596-109608. doi: 10.18632/oncotarget.22741. eCollection 2017 Dec 12.


Leptomeningeal metastases in non-small-cell lung cancer.

Cheng H, Perez-Soler R.

Lancet Oncol. 2018 Jan;19(1):e43-e55. doi: 10.1016/S1470-2045(17)30689-7. Review.


Positron Emission Tomography-Adjusted Intensity Modulated Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.

Ohri N, Bodner WR, Kabarriti R, Shankar V, Cheng H, Abraham T, Halmos B, Gucalp R, Perez-Soler R, Kalnicki S, Garg M.

Int J Radiat Oncol Biol Phys. 2017 Oct 28. pii: S0360-3016(17)34039-7. doi: 10.1016/j.ijrobp.2017.10.032. [Epub ahead of print]


Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.

Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, Adjei AA, Leighl NB, Aisner SC, Rothman JM, Patel JD, Sborov MD, McDermott SR, Perez-Soler R, Traynor AM, Butts C, Evans T, Shafqat A, Chapman AE, Kasbari SS, Horn L, Ramalingam SS, Schiller JH; ECOG-ACRIN.

Lancet Oncol. 2017 Dec;18(12):1610-1623. doi: 10.1016/S1470-2045(17)30691-5. Epub 2017 Nov 9.


Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer.

Hardin C, Shum E, Singh AP, Perez-Soler R, Cheng H.

Expert Opin Pharmacother. 2017 May;18(7):701-716. doi: 10.1080/14656566.2017.1316374. Epub 2017 Apr 17. Review.


Investigational therapies for squamous cell lung cancer: from animal studies to phase II trials.

Shum E, Wang F, Kim S, Perez-Soler R, Cheng H.

Expert Opin Investig Drugs. 2017 Apr;26(4):415-426. doi: 10.1080/13543784.2017.1302425. Epub 2017 Mar 9. Review.


The Use of Antiangiogenic Agents for Lung Cancer in Elderly Patients: An Expert Panel Discussion Synopsis.

Socinski MA, Chaft JE, Levy B, Riely GJ, Langer CJ, Perez-Soler R, Middleton DL, Gracie-King L, Healy LM.

Clin Lung Cancer. 2017 May;18(3):255-258. doi: 10.1016/j.cllc.2016.12.001. Epub 2017 Jan 5. No abstract available.


18F-Fluorodeoxyglucose/Positron Emission Tomography Predicts Patterns of Failure After Definitive Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.

Ohri N, Bodner WR, Halmos B, Cheng H, Perez-Soler R, Keller SM, Kalnicki S, Garg M.

Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):372-380. doi: 10.1016/j.ijrobp.2016.10.031. Epub 2016 Oct 26.


Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer.

Li T, Piperdi B, Walsh WV, Kim M, Beckett LA, Gucalp R, Haigentz M Jr, Bathini VG, Wen H, Zhou K, Pasquinelli PB, Gajavelli S, Sreedhara M, Xie X, Lara PN Jr, Gandara DR, Perez-Soler R.

Clin Lung Cancer. 2017 Jan;18(1):60-67. doi: 10.1016/j.cllc.2016.10.003. Epub 2016 Oct 28.


HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.

Cheng H, Janakiram M, Borczuk A, Lin J, Qiu W, Liu H, Chinai JM, Halmos B, Perez-Soler R, Zang X.

Clin Cancer Res. 2017 Feb 1;23(3):825-832. doi: 10.1158/1078-0432.CCR-15-3071. Epub 2016 Aug 23.


Speaking the same language: a feasibility trial for a novel visual communication tool for oncologist-patient treatment discussions.

Zanartu CP, Camacho FJ, Nevadunski NS, Martin B, Kornblum N, Chuy J, Perez-Soler R.

Psychooncology. 2017 Jul;26(7):1050-1052. doi: 10.1002/pon.4246. Epub 2016 Sep 15. No abstract available.


Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer.

Im JS, Herrmann AC, Bernatchez C, Haymaker C, Molldrem JJ, Hong WK, Perez-Soler R.

PLoS One. 2016 Jul 28;11(7):e0160004. doi: 10.1371/journal.pone.0160004. eCollection 2016.


Associations of Insulin and IGFBP-3 with Lung Cancer Susceptibility in Current Smokers.

Ho GYF, Zheng SL, Cushman M, Perez-Soler R, Kim M, Xue X, Wang T, Schlecht NF, Tinker L, Rohan TE, Wassertheil-Smoller S, Wallace R, Chen C, Xu J, Yu H.

J Natl Cancer Inst. 2016 Apr 12;108(7). doi: 10.1093/jnci/djw012. Print 2016 Jul.


Pax5 Re-expression in H460 Cells Treated with the Combination of Demethylating Agent and Histone Deacetylase Inhibitor is Associated with the Enhancement of P53 Binding to Pax5 Promoter Region.

Liang Y, Zeng J, Jelicks L, Ma S, Liu J, Mei J, Perez-Soler R, Zou Y.

Curr Cancer Drug Targets. 2017;17(2):169-176. doi: 10.2174/1568009616666160331124759.


Medical Treatment in Elderly Patients with Non-Small Cell Lung Cancer.

Bakirhan K, Sharma J, Perez-Soler R, Cheng H.

Curr Treat Options Oncol. 2016 Mar;17(3):13. doi: 10.1007/s11864-016-0388-2. Review.


Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells.

Cheng H, Zhang Z, Rodriguez-Barrueco R, Borczuk A, Liu H, Yu J, Silva JM, Cheng SK, Perez-Soler R, Halmos B.

Oncotarget. 2016 May 17;7(20):28976-88. doi: 10.18632/oncotarget.6721.


Toxicity and Pharmacokinetic Studies of Aerosolized Clinical Grade Azacitidine.

Qiu X, Liang Y, Sellers RS, Perez-Soler R, Zou Y.

Clin Lung Cancer. 2016 May;17(3):214-222.e1. doi: 10.1016/j.cllc.2015.09.005. Epub 2015 Oct 22.


RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.

Cheng H, Zou Y, Ross JS, Wang K, Liu X, Halmos B, Ali SM, Liu H, Verma A, Montagna C, Chachoua A, Goel S, Schwartz EL, Zhu C, Shan J, Yu Y, Gritsman K, Yelensky R, Lipson D, Otto G, Hawryluk M, Stephens PJ, Miller VA, Piperdi B, Perez-Soler R.

Cancer Discov. 2015 Dec;5(12):1262-70. doi: 10.1158/2159-8290.CD-14-0971. Epub 2015 Sep 14.


In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC Jr, Bennett JM, Benz EJ Jr, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ Jr, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA.

Mayo Clin Proc. 2015 Aug;90(8):996-1000. doi: 10.1016/j.mayocp.2015.06.001. Epub 2015 Jul 23. No abstract available.


Emerging treatment for advanced lung cancer with EGFR mutation.

Inal C, Yilmaz E, Piperdi B, Perez-Soler R, Cheng H.

Expert Opin Emerg Drugs. 2015;20(4):597-612. doi: 10.1517/14728214.2015.1058778. Epub 2015 Jul 8. Review.


Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cells.

Nordstrøm LU, Sironi J, Aranda E, Maisonet J, Perez-Soler R, Wu P, Schwartz EL.

ACS Med Chem Lett. 2015 Jan 8;6(2):134-9. doi: 10.1021/ml500348p. eCollection 2015 Feb 12.


Emerging drugs for squamous cell lung cancer.

Cheng H, Shcherba M, Kandavelou K, Liang Y, Liu H, Perez-Soler R.

Expert Opin Emerg Drugs. 2015 Mar;20(1):149-60. doi: 10.1517/14728214.2015.1001365. Epub 2015 Jan 5. Review.


Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.

Ohri N, Piperdi B, Garg MK, Bodner WR, Gucalp R, Perez-Soler R, Keller SM, Guha C.

Lung Cancer. 2015 Jan;87(1):23-7. doi: 10.1016/j.lungcan.2014.10.016. Epub 2014 Nov 6.


Aerosol azacytidine inhibits orthotopic lung cancers in mice through Its DNA demethylation and gene reactivation effects.

Qiu X, Liang Y, Sellers RS, Perez-Soler R, Zou Y.

PLoS One. 2014 Oct 27;9(10):e109874. doi: 10.1371/journal.pone.0109874. eCollection 2014.


Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment.

Cheng H, Shcherba M, Pendurti G, Liang Y, Piperdi B, Perez-Soler R.

Lung Cancer Manag. 2014 Jan 1;3(1):67-75.


Cell cycle inhibitors for the treatment of NSCLC.

Shcherba M, Liang Y, Fernandes D, Perez-Soler R, Cheng H.

Expert Opin Pharmacother. 2014 May;15(7):991-1004. doi: 10.1517/14656566.2014.902935. Epub 2014 Mar 25. Review.


Targeting angiogenesis in squamous non-small cell lung cancer.

Piperdi B, Merla A, Perez-Soler R.

Drugs. 2014 Mar;74(4):403-13. doi: 10.1007/s40265-014-0182-z. Review.


Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).

Ramalingam S, Crawford J, Chang A, Manegold C, Perez-Soler R, Douillard JY, Thatcher N, Barlesi F, Owonikoko T, Wang Y, Pultar P, Zhu J, Malik R, Giaccone G; FORTIS-M Study Investigators.

Ann Oncol. 2013 Nov;24(11):2875-80. doi: 10.1093/annonc/mdt371. Epub 2013 Sep 19.


Retraction: The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab.

Perez-Soler R, Zou Y, Li T, Ling YH.

Clin Cancer Res. 2013 Sep 1;19(17):4901. doi: 10.1158/1078-0432.CCR-13-1912. No abstract available.


Retraction: PM02734 (elisidepsin) induces caspase-independent cell death associated with features of autophagy, inhibition of the Akt/mTOR signaling pathway, and activation of death-associated protein kinase.

Ling YH, Aracil M, Zou Y, Yuan Z, Lu B, Jimeno J, Cuervo AM, Perez-Soler R.

Clin Cancer Res. 2013 Sep 1;19(17):4900. doi: 10.1158/1078-0432.CCR-13-1910. No abstract available.


The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib.

Zou Y, Ling YH, Sironi J, Schwartz EL, Perez-Soler R, Piperdi B.

J Thorac Oncol. 2013 Jun;8(6):693-702. doi: 10.1097/JTO.0b013e31828c7210.


Role of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patients.

Piperdi B, Perez-Soler R.

Drugs. 2012 Jun 19;72 Suppl 1:11-9. doi: 10.2165/1163018-S0-000000000-00000. Review.


Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer.

Piperdi B, Walsh WV, Bradley K, Zhou Z, Bathini V, Hanrahan-Boshes M, Hutchinson L, Perez-Soler R.

J Thorac Oncol. 2012 Jun;7(6):1032-40. doi: 10.1097/JTO.0b013e31824de2fa.


Mechanisms of resistance to vascular endothelial growth factor blockade.

Abdullah SE, Perez-Soler R.

Cancer. 2012 Jul 15;118(14):3455-67. doi: 10.1002/cncr.26540. Epub 2011 Nov 15. Review.


Bortezomib: understanding the mechanism of action.

Piperdi B, Ling YH, Liebes L, Muggia F, Perez-Soler R.

Mol Cancer Ther. 2011 Nov;10(11):2029-30. doi: 10.1158/1535-7163.MCT-11-0745. No abstract available.


The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab.

Perez-Soler R, Zou Y, Li T, Ling YH.

Clin Cancer Res. 2011 Nov 1;17(21):6766-77. doi: 10.1158/1078-0432.CCR-11-0545. Epub 2011 Sep 13. Retraction in: Perez-Soler R, Zou Y, Li T, Ling YH. Clin Cancer Res. 2013 Sep 1;19(17):4901.


Treatment of non-small-cell lung cancer with erlotinib or gefitinib.

Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A.

N Engl J Med. 2011 Mar 10;364(10):947-55. doi: 10.1056/NEJMct0807960. Review.


Both gene amplification and allelic loss occur at 14q13.3 in lung cancer.

Harris T, Pan Q, Sironi J, Lutz D, Tian J, Sapkar J, Perez-Soler R, Keller S, Locker J.

Clin Cancer Res. 2011 Feb 15;17(4):690-9. doi: 10.1158/1078-0432.CCR-10-1892. Epub 2010 Dec 10.


Intratracheally administered 5-azacytidine is effective against orthotopic human lung cancer xenograft models and devoid of important systemic toxicity.

Mahesh S, Saxena A, Qiu X, Perez-Soler R, Zou Y.

Clin Lung Cancer. 2010 Nov 1;11(6):405-11. doi: 10.3816/CLC.2010.n.052.


EGFR TKIs for advanced NSCLC: practical questions.

Perez-Soler R.

Oncology (Williston Park). 2010 Apr 30;24(5):400-1, 409. No abstract available.


Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer.

Li T, Lara PN Jr, Mack PC, Perez-Soler R, Gandara DR.

Curr Drug Targets. 2010 Jan;11(1):85-94. Review.


Individualized therapy in non-small-cell lung cancer: future versus current clinical practice.

Pérez-Soler R.

Oncogene. 2009 Aug;28 Suppl 1:S38-45. doi: 10.1038/onc.2009.200. Review.


Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).

Li T, Ho L, Piperdi B, Elrafei T, Camacho FJ, Rigas JR, Perez-Soler R, Gucalp R.

Lung Cancer. 2010 Apr;68(1):89-93. doi: 10.1016/j.lungcan.2009.05.009. Epub 2009 Jun 12.


Skin toxicities associated with epidermal growth factor receptor inhibitors.

Li T, Perez-Soler R.

Target Oncol. 2009 Apr;4(2):107-19. doi: 10.1007/s11523-009-0114-0. Epub 2009 May 19. Review.


Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models.

Ling YH, Aracil M, Jimeno J, Perez-Soler R, Zou Y.

Eur J Cancer. 2009 Jul;45(10):1855-64. doi: 10.1016/j.ejca.2009.03.003. Epub 2009 Apr 5.


Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib.

Ling YH, Li T, Perez-Soler R, Haigentz M Jr.

Cancer Chemother Pharmacol. 2009 Aug;64(3):539-48. doi: 10.1007/s00280-008-0902-8. Epub 2009 Jan 8.


Supplemental Content

Loading ...
Support Center